GlassScriptPhysician profile
Naresh Reddivalla
NPI 1073851150
$1,491.22
in general payments reported to CMS, 2019-2025
12 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $35.46 · 2021: $74.62 · 2022: $47.49 · 2023: $27.06 · 2024: $1,056 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $837 · Food and Beverage: $496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $837.29 |
| Food and Beverage | $496.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $907.38 | 2024 | Clonoseq |
| Uswm, LLC | $133.33 | 2024-2025 | Iwilfin |
| Jazz Pharmaceuticals INC. | $107.97 | 2024-2025 | |
| Sobi, INC | $103.77 | 2021-2025 | |
| Eton Pharmaceuticals, INC. | $62.78 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.65 | 2025 | |
| Sanofi-Aventis U.S. LLC | $34.66 | 2024 | |
| Advanced Oxygen Therapy INC. | $30.04 | 2025 | Topical Oxygen Chamber For Extremities |
| Daiichi Sankyo INC. | $27.19 | 2025 | Injectafer |
| Genzyme Corporation | $13.38 | 2021 | |
| Seagen INC. | $12.57 | 2022 | |
| United Therapeutics Corporation | $12.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naresh Reddivalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.